Get the app
US › Healthcare

Minerva Neurosciences Inc (NERV)

US · Healthcare · Biotechnology

$2.42+5.22%
Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$17.5M
EPS
$-0.46
EPS estimate
$-0.01

EPS came in at -0.46 against a street estimate of -0.01 — a miss of 4500.0%.

Key statistics

Market cap
$109.8M
Forward P/E
11.2
P/B
2.68
Book value
$-4.52
EPS (TTM)
$-36.12
52-week high
$8.80
52-week low
$1.96
50-day MA
$3.34
200-day MA
$4.87
Beta
0.01

Analyst view

Analysts rate Minerva Neurosciences Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $10.33.

Shareholding

Insiders
3.26%
Institutions
93.16%

Largest institutional holders

FundStake
Federated Hermes Inc9.78%
Jupiter Topco LLC9.19%
Vivo Capital, LLC9.05%
Balyasny Asset Management LLC8.92%
Logos Global Management LP6.89%
Farallon Capital Management, L.L.C.4.95%
BlackRock Inc4.69%
Ally Bridge Group (NY) LLC4.56%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Minerva Neurosciences Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-11-07.